Dianthus Therapeutics Inc. (DNTH)
Summary
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 15 | $272 | $1,495.65 | $1,223.65 | 449.87% |
 Farallon Capital Farallon Capital Management LLC | 836,000 | $70.16M | $83.53M | $13.38M | 19.07% |
| BG Bart Gancher Intech Investment Management LLC | 7,465 | $370,160.09 | $748,274.43 | $378,114.34 | 102.15% |
 John H. Burbank III Passport Capital LLC | 852,164 | $19.95M | $85.42M | $65.47M | 328.16% |
 Point72 Asset Management LP Point72 Asset Management LP | 643,599 | $25.33M | $64.59M | $39.26M | 155.02% |
Dianthus Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SS Steven Seedhouse Raymond James | 43.12 | $3,748 | $4,056.52 | $308.52 | 8.23% |
Dianthus Therapeutics Inc. (DNTH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dianthus Therapeutics Inc. ever had a stock split?
Dianthus Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Marino Garcia CEO | NASDAQ (CM) Exchange | 252828108 CUSIP |
| US Country | 92 Employees | - Last Dividend | - Last Split | 12 Sep 2023 IPO Date |
Overview
Dianthus Therapeutics, Inc. stands as a pivotal clinical-stage biotechnology enterprise dedicated to the innovation of complement therapeutics aimed at addressing the unmet needs of patients suffering from severe autoimmune and inflammatory diseases. Founded in 2019 and with its headquarters in New York, New York, Dianthus Therapeutics leverages its expertise in developing cutting-edge treatments that promise to redefine the landscape of autoimmune and inflammatory disease management. Through rigorous research and development efforts, Dianthus is at the forefront of producing monoclonal antibodies designed to combat a range of debilitating conditions, reflecting its commitment to improving patient outcomes and overall quality of life.
Products and Services
-
DNTH103
DNTH103 occupies a central role in Dianthus Therapeutics, Inc.'s product pipeline as a monoclonal antibody currently advancing through Phase 2 clinical trial. Emblematic of the company's cutting-edge approach to biotechnology, DNTH103 is engineered to target and ameliorate conditions stemming from autoimmune and inflammatory diseases. This includes generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder that leads to varying degrees of skeletal muscle weakness. The scope of DNTH103's application extends to multifocal motor neuropathy, a rare nerve disease characterized by progressive muscle weakness and atrophy, as well as chronic inflammatory demyelinating polyneuropathy, a neurological disorder that causes sensory loss and motor dysfunction. By focusing on these conditions, DNTH103 exemplifies Dianthus Therapeutics' dedication to developing therapeutic solutions that have the potential to significantly enhance the lives of patients dealing with severe autoimmune and inflammatory diseases.
